打开APP

瑞士Basilea公司欢迎美国公司收购凸显美国生物医药行业税率问题

  1. Basilea
  2. 医药
  3. 收购
  4. 税率

来源:生物谷 2014-08-15 09:44

就在几周前,瑞士生物医药公司Basilea开发的新型抗生素药物ceftobiprole未能获得FDA的上市批准。

2014年8月15日讯 /生物谷BIOON/ --就在几周前,瑞士生物医药公司Basilea开发的新型抗生素药物ceftobiprole未能获得FDA的上市批准,FDA要求Basilea公司进行两项额外的临床三期研究后才会考虑这一药物在美国的上市问题。这也以为着Basilea公司需要花费更多的人力物力才可能获得ceftobiprole在美国的上市许可。

而最近公司的CEO Ronald Scott则公开表示,有鉴于此,公司下一步将可能会寻求将公司整体出售给美国的生物医药公司。但是千万不要以为Basilea公司是属于"垃圾股"无人问津。今年来,许多美国本土的生物医药公司都苦于本国过高的税率,而采取海外并购的方式变更公司注册地。而欧洲国家如英国、瑞士等都因为本国对于生物医药公司优惠的税率而成为重点关注的对象。Ronald Scott在接受采访时表示,公司欢迎愿意给出足以体现公司资产价值并保证股东利益的价格的公司进行收购。

而近年来,出于降低税率而进行的收购案在生物医药行业屡见不鲜。辉瑞收购阿斯利康公司的初衷之一就是看中了英国远低于美国的税率。另外艾伯维突然收购Shire公司也同样如此。海外收购虽然节省了生物医药公司的大量税务开支,但却苦了掌管美国国库的财务官。总统奥巴马此前就曾为此指责各大生物技术公司并要求税务部门补上这一漏洞。因此从长远来看,大型生物医药公司的海外并购审核将越来越严格。但是考虑到Basilea公司的年销售额不到10亿美元,因此管理部门对这一层次的公司监管并不如其他巨头那么严格。如果美国的生物医药公司希望搭上通过海外并购而避税的末班车,那Basilea显然是个不错的选择。(生物谷Bioon.com)

详细英文报道:

A few weeks ago the FDA officially barred Basilea's new antibiotic ceftobiprole from the U.S. markets, sticking with its demand for two late-stage studies before it offers a regulatory green light for marketing. So today Basilea CEO Ronald Scott offered that the next best step for the biotech may be to just sell the Basel-based company to a U.S.-based biopharma company interested in a quick tax inversion deal that would allow a buyer the chance of trading American taxes for a sweeter deal in Switzerland.

Scott, a Swiss national as well as the former CFO, has been signaling his interest in a deal of some kind for a while now. Ceftobiprole is approved in Europe and beginning an H2 rollout, starting in Germany. But Scott noted recently that with the FDA sticking by its decision that it would need to see a second batch of confirmatory data, there would be no new study without a partner to cover the tab.

Now, while most companies play coy about selling the company and swiftly reject initial overtures as an insulting lowball offer, Scott is ready to talk terms with interested bidders.

"A Swiss company and a Swiss holding lends itself to these transactions," Scott told Bloomberg in an interview. "We are open to structures that create value for our shareholders and also create the most value for our assets."

Pfizer ($PFE) may have been unsuccessful--at least initially--in its effort to buy AstraZeneca ($AZN) in a deal that only seemed to make sense to analysts as a straightforward tax dodge: dump the U.S. tax man and his high rates in exchange for the much lower U.K. assessment for corporations. But the pharma giant shoved tax inversions right into the center stage of global biopharma finance. And AbbVie ($ABBV) moved fast to scoop up Shire ($SHPG) in the sudden rush that followed. Now Treasury officials are threatening to find a swift administrative remedy to block the gambit. But Scott says smaller fish like Basilea--with a market cap north of $1 billion--may still escape any net put out by the feds.

Scott tells Bloomberg: "Certainly these megamergers will come under political scrutiny. Maybe the smaller ones can still take place."

 

版权声明 本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。非经授权,任何媒体、网站或个人不得转载,否则将追究法律责任。取得书面授权转载时,须注明“来源:生物谷”。其它来源的文章系转载文章,本网所有转载文章系出于传递更多信息之目的,转载内容不代表本站立场。不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。

87%用户都在用生物谷APP 随时阅读、评论、分享交流 请扫描二维码下载->